Radiolabeled Biodistribution of Expansile Nanoparticles: Intraperitoneal Administration Results in Tumor Specific Accumulation
Open Access
- 26 January 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 17 (3) , 2212-2221
Abstract
Nanoparticle biodistribution in vivo is an essential component to the success of nanoparticle-based drug delivery systems. Previous studies with fluorescently labeled expansile nanoparticles, or "eNPs", demonstrated a high specificity of eNPs to tumors that is achieved through a materials-based targeting strategy. However, fluorescent labeling techniques are primarily qualitative in nature and the gold-standard for quantitative evaluation of biodistribution is through radiolabeling. In this manuscript, we synthesize 14C-labeled eNPs to quantitatively evaluate the biodistribution of these particles in a murine model of intraperitoneal mesothelioma via liquid scintillation counting. The results demonstrate a strong specificity of eNPs for tumors that lasts one to 2 weeks postinjection with an overall delivery efficiency to the tumor tissue of 30% of the injected dose which is congruent with prior reports of preclinical efficacy of the technology. Importantly, the route of administration is essential to the eNP's material-based targeting strategy with intraperitoneal administration leading to tumoral accumulation while, in contrast, intravenous administration leads to rapid clearance via the reticuloendothelial system and low tumoral accumulation. A comparison against nanoparticle delivery systems published over the past decade shows that the 30% tumoral delivery efficiency of the eNP is significantly higher than the 0.7% median delivery efficiency of other systems with sufficient quantitative data to define this metric. These results lay a foundation for targeting intraperitoneal tumors and encourage efforts to explore alternative, nonintravenous routes, of delivery to accelerate the translation of nanoparticle therapies to the clinic.Keywords
Funding Information
- National Cancer Institute (R01 CA227433, R01 CA232056, R43 CA189215, R43 CA213538, R44 CA189215)
- National Institute of Biomedical Imaging and Bioengineering (T32 EB006359)
This publication has 44 references indexed in Scilit:
- Biotargeted Nanomedicines for Cancer: Six Tenets Before You BeginNanomedicine, 2013
- Paclitaxel-Loaded Expansile Nanoparticles in a Multimodal Treatment Model of Malignant MesotheliomaThe Annals of Thoracic Surgery, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosisBiomaterials, 2011
- Factors Affecting the Clearance and Biodistribution of Polymeric NanoparticlesMolecular Pharmaceutics, 2008
- Clinical Efficacy Supporting the Role of Intraperitoneal Drug Delivery in the Primary Chemotherapeutic Management of Small-Volume Residual Advanced Ovarian CancerSeminars in Oncology, 2006
- Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancerGynecologic Oncology, 2005
- The Hallmarks of CancerCell, 2000
- Vascular clearance by the reticuloendothelial system—measurements using two different-sized albumin colloidsScandinavian Journal of Clinical and Laboratory Investigation, 1990
- Studies of the Reticuloendothelial System (RES). III. Blockade of the RES in Man *Journal of Clinical Investigation, 1964